Image 3_Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review.tif حسب Leqing Zhou (20981021)

"…Objective<p>Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and meta-analysis comparing the long-term oncologic and renal function outcomes of KSS with those of radical nephroureterectomy (RNU) for UTUC.…"

Table 1_Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review.docx حسب Leqing Zhou (20981021)

"…Objective<p>Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and meta-analysis comparing the long-term oncologic and renal function outcomes of KSS with those of radical nephroureterectomy (RNU) for UTUC.…"

Image 1_Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review.tif حسب Leqing Zhou (20981021)

"…Objective<p>Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and meta-analysis comparing the long-term oncologic and renal function outcomes of KSS with those of radical nephroureterectomy (RNU) for UTUC.…"

Image 2_Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review.tif حسب Leqing Zhou (20981021)

"…Objective<p>Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and meta-analysis comparing the long-term oncologic and renal function outcomes of KSS with those of radical nephroureterectomy (RNU) for UTUC.…"

Table 1_Loneliness and mental burden among German medical students during the fading COVID-19 pandemic: a mixed-methods approach.docx حسب Marvik Leich (20930363)

"…This study aims to address this gap.</p>Methods<p>We performed a cross-sectional study at a German Medical School, consisting of two online surveys conducted in winter 2021/22 and summer 2022. …"

A well-resolved phylogeny of <i>Epilobium</i> (Onagraceae) taxa in the British Isles finds no correlation between genomic divergence and the outcome of hybridisation حسب Kaitlin Saward (22126620)

"…All were likely to be F₁ hybrids.</p> <p>We did not detect a significant relationship between parental divergence and hybridisation likelihood and/or hybrid fertility in <i>Epilobium</i> sect. …"

DataSheet1_Efficacy of combination therapy of vitamin D and bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis.zip حسب Yuangui Yang (6746633)

"…However, the combination of VitD and bisphosphonates did not show a significant advantage over monotherapy in terms of improving osteocalcin levels. …"

Data Sheet 5_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.pdf حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Data Sheet 2_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.xlsx حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Data Sheet 6_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.pdf حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Data Sheet 3_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.xlsx حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Data Sheet 1_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.docx حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Data Sheet 4_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.pdf حسب Yi-Ming Ren (555968)

"…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …"

Image 3_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg حسب Bingtao Hu (16784702)

"…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …"

Image 2_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg حسب Bingtao Hu (16784702)

"…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …"

Image 4_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg حسب Bingtao Hu (16784702)

"…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …"

Image 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg حسب Bingtao Hu (16784702)

"…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …"

Table 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.docx حسب Bingtao Hu (16784702)

"…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …"

Table 1_Global burden of lower respiratory infections attributable to cytomegalovirus, 1990–2021: a systematic analysis from the MICROBE database.docx حسب Wanwan Zhang (1550911)

"…From 1990 to 2021, both ASMR and ASDR for CMV-attributable LRI decreased as SDI increased, and projections indicate a continued decline over the next 30 years.…"

Data Sheet 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.xlsx حسب Demos Kynigopoulos (12420457)

"…Increasing evidence implicates systemic metabolic dysregulation in AD pathogenesis, yet it remains unclear whether modulation of peripheral lipid and glucose metabolism can alter disease progression.</p>Methods<p>We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. …"